Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

AIMS: To study long-term, whole population 'real-world' clinical outcomes of ranibizumab therapy in treatment-naïve eyes for neovascular age-related macular degeneration. METHODS: Data collected prospectively from a single centre serving a defined population using an electronic medical record included: demographics, Early Treatment Diabetic Retinopathy Study visual acuity (ETDRS VA) at all visits, injection dates, central 1 mm retinal thickness, and operative and postoperative complications. RESULTS: 1483 eyes from 1278 patients were included in this study. The median age at the time of the patient's first injection was 82.5 years, 64.9% of patients were female, and another ocular pathology was present in 7.3% eyes. The baseline VA was 23-39, 40-54, 55-70 and >70 ETDRS letters for 17.3%, 23.1%, 42.7% and 16.9% of eyes, respectively. The median VA in all baseline VA groups improved after the loading phase but declined back to the baseline level by 2-5 years. The rate of endophthalmitis following intravitreal injection was 1 in 2124 injections. CONCLUSIONS: These long-term real-world data demonstrate that in general VA increases during the loading phase but returns to near baseline levels after 2-5 years of treatment for each baseline VA category. Patients should be identified and treated as early as possible, since presenting VA predicts the VA maintained after 5 years of treatment. National Institute of Health and Care Excellence guidance advising treatment only for eyes with vision below 70 letters does not promote best long-term VA outcomes for patients.

Original publication

DOI

10.1136/bjophthalmol-2014-306423

Type

Journal article

Journal

Br j ophthalmol

Publication Date

02/2016

Volume

100

Pages

240 - 245

Keywords

Aged, Aged, 80 and over, Angiogenesis Inhibitors, Female, Follow-Up Studies, Humans, Intraoperative Complications, Intravitreal Injections, Male, Middle Aged, Postoperative Complications, Prospective Studies, Ranibizumab, Treatment Outcome, United Kingdom, Vascular Endothelial Growth Factor A, Visual Acuity, Wet Macular Degeneration